2024 ASCO® Annual Meeting Insights Hub
Meeting coverage & Vumedi’s exclusive highlights, all in one place.
ASCO® 2024 Insights: "Safety & Efficacy of First-in-Class CXCR1/2 Inhibitor SX-682 in Combination With Pembro in Patients With Metastatic Melanoma With Disease Progression on Anti-PD-1 Therapy"
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Sapna Patel
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Sapna Patel
Comments 0
Login to view comments.
Click here to Login
